Quick answer
What is Ipamorelin?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Ipamorelin is a peptide, grouped on this site under Growth hormone secretagogues, and the 12 research records kept here are 7 from studies in rats or mice, 2 from trials in people and 3 that do not state what kind of study it is.
The literature search returned 63 records. This site keeps 12 of them, which is 19 per cent of what came back.
What it is
This site puts it in the Growth hormone secretagogues group.
A selective growth hormone secretagogue and ghrelin mimetic, acting at the growth hormone secretagogue receptor.[1, 2]
Stated in the titles of the cited 1998 European Journal of Endocrinology and 2009 Journal of Pharmacology and Experimental Therapeutics papers.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 2 interventional human trial records among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 51 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). pmid:9849822
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther (2009). pmid:19289567